INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 428s ago
HOUSE PTR8s ago
SEC 13F1s ago
ROBINHOOD CHAIN1s ago
SEC FORM 4/Open-market saleVerified data

Levy Adam Scott sold MLYS

CFO and Secretary · Mineralys Therapeutics, Inc. · Common Stock

Side
SELL
Value
$539K
Shares
13.0K
Price
$41.65
Executed
Nov 11, 2025
Disclosed
Nov 13, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 11 executedNov 13, 2025 disclosed

MLYS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
46/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+11 / 25

    $539K reported value · 10.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    4 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MLYS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    12.4K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    16.6K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PK
    Peterson KristineDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    12.4K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PK
    Peterson KristineDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    16.6K sh
    		Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    		+1dSEC FORM 4

    Evidence

    31
    ST
    Slingsby Brian TaylorDirector
    MLYSMineralys Therapeutics, Inc.
    Open-market sale
    		SELL$3.01M
    104.3K sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$209K
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$98K
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,438 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$193K
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$98K
    7,437 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    135.0K sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    		A—
    102.4K sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    6
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$59K
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$35K
    2,170 sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$1.38M
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    41
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.70M
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    11
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    104.1K sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CJ
    Congleton JonDirector, Chief Executive Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$456K
    17.0K sh
    		Jun 30, 2026Jun 30, 2026
    traded Jun 30, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001933414-25-000152
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 11, 2025
    Published
    Nov 13, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Levy Adam Scott
    Role
    CFO and Secretary
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Mineralys Therapeutics, Inc.
    Ticker
    MLYS
    Shares
    13.0K
    Price per share
    $41.65
    Value
    $539,479
    Execution date (reported)
    Nov 11, 2025
    Owned after transaction
    112.1K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 13.0K
    • Price: $41.6522

    = $539,479

    What this establishes

    Levy Adam Scott filed this Form 4 reporting a open-market sale of MLYS on Nov 11, 2025. It became public on Nov 13, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CFO and Secretary
    Levy Adam Scottcik:0001693134
    Issuer
    Mineralys Therapeutics, Inc.cik:0001933414

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.